Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Non-randomized, Open Label, Multi-centre Clinical Trial to Investigate the Safety and Efficacy of [18F]PSMA-1007 Injection in Men With Suspected Persistent or Recurrent Prostate Cancer.

NCT04644822 is registered in ClinicalTrials.gov with Centre for Probe Development and Commercialization as lead sponsor.

NCT NCT04644822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04644822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Non-randomized, Open Label, Multi-centre Clinical Trial to Investigate the Safety and Efficacy of [18F]PSMA-1007 Injection in Men With Suspected Persistent or Recurrent Prostate Cancer.
Lead sponsor
Centre for Probe Development and Commercialization
Phase
Phase 3
Overall status
Completed
Start date
December 21, 2020
Completion date
January 8, 2024
Enrollment
100 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer recurrent, recurrent prostate cancer